Context. - Although clinical trials have demonstrated the benefits of lipid-lowering therapy, little is known about how these drugs are prescribed or used in the general population.
- To estimate predictors of persistence with therapy for lipid-lowering drug regimens in typical populations of patients in the United States and Canada.
- A cohort study defining all prescriptions filled for lipid-lowering drugs during 1 year, as well as patients'demographic and clinical characteristics.
- New Jersey's Medicaid and Pharmacy Assistance for the Aged and Disabled programs and Quebec's provincial medical care program.
- All continuously enrolled patients older than 65 years who filled 1 or more prescriptions for lipid-lowering-drugs (N=5611 in the US programs, and N=1676 drawn from a 10% sample in Quebec).
- Proportion of days during the study year for which patients had filled prescriptions for lipid-lowering drugs ; predictors of good vs poor persistence with therapy.
- In both populations, patients failed to fill prescriptions for lipid-lowering drugs for about 40% of the study year.
Persistence rates with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were significantly higher than those seen with cholestyramine (64.3% vs 36.6% of days with drug available, respectively). (...)
Mots-clés Pascal : Hypolipémiant, Prescription médicale, Statistique descriptive, Hyperlipémie, Chimiothérapie, Traitement, Homme, Canada, Amérique du Nord, Amérique, Etats Unis, Lipide, Métabolisme pathologie, Dyslipémie
Mots-clés Pascal anglais : Antilipemic agent, Medical prescription, Descriptive statistics, Hyperlipemia, Chemotherapy, Treatment, Human, Canada, North America, America, United States, Lipids, Metabolic diseases, Dyslipemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0261171
Code Inist : 002B02N. Création : 11/09/1998.